Efficacy and safety of secukinumab in the treatment of moderate to severe plaque psoriasis: A meta-analysis of randomized controlled trials

International Journal of Clinical and Experimental Medicine

Volumn 8, Issue 3, 2015, Pages 3156-3172

  Xiong, Hui Zi ^a,b   Gu, Jun Ying ^a   He, Zhi Gang ^a   Chen, Wen Juan ^a   Zhang, Xiao ^a   Wang, Jia Yi ^a   Shi, Yu Ling ^a  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^b THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

Author keywords

Meta analysis; Psoriasis; Secukinumab

Indexed keywords

SECUKINUMAB;

ARTICLE; BACKACHE; BODY SURFACE; DRUG EFFICACY; DRUG SAFETY; HEADACHE; HUMAN; HYPERTENSION; INFECTION; META ANALYSIS; PATIENT SATISFACTION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRURITUS; PSORIASIS SEVERITY INDEX; PSORIASIS VULGARIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHINOPHARYNGITIS;

EID: 84929158936     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Ohtsuki M, Morita A, Abe M, Takahashi H, Seko N, Karpov A, Shima T, Papavassilis C and Nakagawa H. Secukinumab efficacy and safety in Japanese patients with moderate-to-severe plaque psoriasis: subanalysis from ERASURE, a randomized, placebo-controlled, phase 3 study. J Dermatol 2014; 41: 1039-46.
2. Ryan C and Kirby B. Psoriasis is a systemic disease with multiple cardiovascular and metabolic comorbidities. Dermatol Clin 2015; 33: 41-55.
3. Menter A, Gottlieb A, Feldman SR, Van Voorhees AS, Leonardi CL, Gordon KB, Lebwohl M, Koo JY, Elmets CA, Korman NJ, Beutner KR and Bhushan R. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008; 58: 826-850.
4. Posso-De Los Rios CJ, Pope E and Lara-Corrales I. A systematic review of systemic medications for pustular psoriasis in pediatrics. Pediatr Dermatol 2014; 31: 430-439.
5. Yiu ZZ, Warren RB, Mrowietz U and Griffiths CE. Safety of conventional systemic therapies for psoriasis on reproductive potential and outcomes. J Dermatolog Treat 2015; 1-6.
6. Cather JC and Crowley JJ. Use of biologic agents in combination with other therapies for the treatment of psoriasis. Am J Clin Dermatol 2014; 15: 467-478.
7. Brezinski EA and Armstrong AW. Strategies to maximize treatment success in moderate to severe psoriasis: establishing treatment goals and tailoring of biologic therapies. Semin Cutan Med Surg 2014; 33: 91-97.
8. Kivelevitch D, Mansouri B and Menter A. Long term efficacy and safety of etanercept in the treatment of psoriasis and psoriatic arthritis. Biologics 2014; 8: 169-182.
9. Chiricozzi A. Pathogenic role of IL-17 in psoriasis and psoriatic arthritis. Actas Dermosifiliogr 2014; 105 Suppl 1: 9-20.
10. Tausend W, Downing C and Tyring S. Systematic review of interleukin-12, interleukin-17, and interleukin-23 pathway inhibitors for the treatment of moderate-to-severe chronic plaque psoriasis: ustekinumab, briakinumab, tildrakizumab, guselkumab, secukinumab, ixekizumab, and brodalumab. J Cutan Med Surg 2014; 18: 156-169.
11. Kurzeja M, Rudnicka L and Olszewska M. New interleukin-23 pathway inhibitors in dermatology: ustekinumab, briakinumab, and secukinu-mab. Am J Clin Dermatol 2011; 12: 113-125.
12. Mazur M, Karczewski J, Lodyga M, Zaba R and Adamski Z. Inhibitors of phosphodiesterase 4 (PDE 4): a new therapeutic option in the treatment of psoriasis vulgaris and psoriatic arthritis. J Dermatolog Treat 2014; 1-13.
13. Papp KA, Sundaram M, Bao Y, Williams DA, Gu Y, Signorovitch JE, Wang Y, Valdes JM and Mulani PM. Effects of briakinumab treatment for moderate to severe psoriasis on health-related quality of life and work productivity and activity impairment: results from a randomized phase III study. J Eur Acad Dermatol Venereol 2014; 28: 790-798.
14. Sigler J. Drug updates and approvals: 2014 in review. Nurse Pract 2014; 39: 14-23.
15. Bissonnette R, Iversen L, Sofen H, Griffiths CE, Foley P, Romiti R, Bachinsky M, Rottinghaus ST, Tan H, Proulx J, Valdez H, Gupta P, Mallbris L and Wolk R. Tofacitinib withdrawal and re-treatment in moderate-to-severe chronic plaque psoriasis: a randomised controlled trial. Br J Dermatol 2014; [Epub ahead of print],.
16. Leonardi CL and Gordon KB. New and emerging therapies in psoriasis. Semin Cutan Med Surg 2014; 33: S37-41.
17. Lynch M, Kirby B and Warren RB. Treating moderate to severe psoriasis-best use of biologics. Expert Rev Clin Immunol 2014; 10: 269-279.
18. Saeki H, Nakagawa H, Ishii T, Morisaki Y, Aoki T, Berclaz PY and Heffernan M. Efficacy and safety of open-label ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis. J Eur Acad Dermatol Venereol 2014; [Epub ahead of print].
19. Papp K, Leonardi C, Menter A, Thompson EH, Milmont CE, Kricorian G, Nirula A and Klekotka P. Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment. J Am Acad Dermatol 2014; 71: 1183-1190.
20. Nedoszytko B, Sokolowska-Wojdylo M, Rucke-mann-Dziurdzinska K, Roszkiewicz J and Nowi-cki RJ. Chemokines and cytokines network in the pathogenesis of the inflammatory skin diseases: atopic dermatitis, psoriasis and skin mastocytosis. Postepy Dermatol Alergol 2014; 31: 84-91.
21. Shabgah AG, Fattahi E and Shahneh FZ. Interleukin-17 in human inflammatory diseases. Postepy Dermatol Alergol 2014; 31: 256-261.
22. Cai Y, Fleming C and Yan J. New insights of T cells in the pathogenesis of psoriasis. Cell Mol Immunol 2012; 9: 302-309.
23. Donetti E, Cornaghi L, Gualerzi A, Baruffaldi Preis FW and Prignano F. An innovative three-dimensional model of normal human skin to study the proinflammatory psoriatic effects of tumor necrosis factor-alpha and interleukin-17. Cytokine 2014; 68: 1-8.
24. Recker K. [Psoriasis. Inhibition of IL-17 signaling pathway by Secukinumab]. Med Monat-sschr Pharm 2014; 37: 267-268.
25. Mrowietz U, Kragballe K, Reich K, Spuls P, Griffiths CE, Nast A, Franke J, Antoniou C, Arenberger P, Balieva F, Bylaite M, Correia O, Dauden E, Gisondi P, Iversen L, Kemeny L, Lahfa M, Nijsten T, Rantanen T, Reich A, Rosenbach T, Segaert S, Smith C, Talme T, Volc-Platzer B and Yawalkar N. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res 2011; 303: 1-10.
26. Puig L. PASI90 response: the new standard in therapeutic efficacy for psoriasis. J Eur Acad Dermatol Venereol 2015; 29: 645-8.
27. Hueber W, Patel DD, Dryja T, Wright AM, Koroleva I, Bruin G, Antoni C, Draelos Z, Gold MH, Psoriasis Study G, Durez P, Tak PP, Gomez-Reino JJ, Rheumatoid Arthritis Study G, Foster CS, Kim RY, Samson CM, Falk NS, Chu DS, Callanan D, Nguyen QD, Uveitis Study G, Rose K, Haider A and Di Padova F. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med 2010; 2: 52ra72.
28. Papp KA, Langley RG, Sigurgeirsson B, Abe M, Baker DR, Konno P, Haemmerle S, Thurston HJ, Papavassilis C and Richards HB. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled ph-ase II dose-ranging study. Br J Dermatol 2013; 168: 412-421.
29. Blauvelt A, Prinz JC, Gottlieb AB, Kingo K, Sofen H, Ruer-Mulard M, Singh V, Pathan R, Papavassilis C, Cooper S; FEATURE Study Group. Secukinumab administration by pre-filled syringe: efficacy, safety, and usability results from a randomized controlled trial in psoriasis (FEATURE). Br J Dermatol 2015; 172: 484-93.
30. Correr CJ, Rotta I, Teles Tde S, Godoy RR, Riveros BS, Garcia MM, Goncalves PR and Otuki MF. Efficacy and safety of biologics in the treatment of moderate to severe psoriasis: a comprehensive meta-analysis of randomized controlled trials. Cad Saude Publica 2013; 29 Suppl 1: s17-31.